In Reply We appreciate the attention from Lim and colleagues to our Viewpoint1 on common myths in the use of levodopa in Parkinson disease (PD). We clarified in our article that the subtitle “When Clinical Trials Misinform Clinical Practice” should mean, if character counts had no limits, “when the interpretation of clinical trials misinform clinical practice.” We do not disagree on this point.
Espay AJ, Lang AE. Levodopa and Parkinson Disease—Myths Revisited—Reply. JAMA Neurol. 2017;74(10):1270–1271. doi:10.1001/jamaneurol.2017.2563
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: